BIOLINERX LTD/S (NASDAQ:BLRX) Rating Increased to Buy at ValuEngine

Share on StockTwits

BIOLINERX LTD/S (NASDAQ:BLRX) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, ValuEngine reports.

Other equities research analysts have also issued research reports about the stock. HC Wainwright set a $25.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 28th. Zacks Investment Research upgraded shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. Finally, Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $2.13.

BLRX opened at $4.28 on Tuesday. The firm has a market capitalization of $33.58 million, a price-to-earnings ratio of -1.36 and a beta of 1.53. BIOLINERX LTD/S has a fifty-two week low of $3.90 and a fifty-two week high of $27.60. The stock’s 50-day simple moving average is $0.59. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.18.

BIOLINERX LTD/S (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). Equities analysts anticipate that BIOLINERX LTD/S will post -2.55 EPS for the current year.

Several large investors have recently made changes to their positions in the business. Delek Group Ltd. acquired a new stake in shares of BIOLINERX LTD/S in the first quarter valued at approximately $92,000. Menta Capital LLC acquired a new stake in shares of BIOLINERX LTD/S in the fourth quarter valued at approximately $33,000. NEXT Financial Group Inc increased its stake in shares of BIOLINERX LTD/S by 82.5% in the second quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 33,000 shares during the period. Deutsche Bank AG acquired a new stake in shares of BIOLINERX LTD/S in the fourth quarter valued at approximately $26,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of BIOLINERX LTD/S in the fourth quarter valued at approximately $25,000. Institutional investors own 33.72% of the company’s stock.

About BIOLINERX LTD/S

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Article: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Macquarie Downgrades Viacom  to Neutral
Macquarie Downgrades Viacom to Neutral
Contrasting Toshiba  & The Competition
Contrasting Toshiba & The Competition
Head to Head Survey: Fanhua  & Its Competitors
Head to Head Survey: Fanhua & Its Competitors
Head-To-Head Survey: Landstar  & Braskem
Head-To-Head Survey: Landstar & Braskem
Deutsche Bank Lowers Deere & Company  Price Target to $155.00
Deutsche Bank Lowers Deere & Company Price Target to $155.00
OMV  Downgraded by Goldman Sachs Group to Neutral
OMV Downgraded by Goldman Sachs Group to Neutral


 
© 2006-2019 Zolmax.